Major study launches to unravel mysteries of rare still disease in kids and adults

NCT ID NCT05927454

Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 500 adults and children with Still disease, a rare inflammatory condition causing fever, joint pain, and rash. Researchers aim to compare how the disease affects different age groups, identify early markers, and improve care. No new treatments are being tested; instead, the goal is to gather information to guide future research and therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to: If successful, this could lead to better understanding of Still disease, earlier diagnosis, and improved treatment strategies for both children and adults.
What could go wrong: This is an observational study, not a treatment trial. It will not directly test any new therapy, and results may take years to impact patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2017

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

In order to reflect the reality of daily practice, all pediatric and adult patients already diagnosed and monitored (prevalent patients) or newly diagnosed (incident patients) in one of the French Rare Disease Reference Center or Rare Disease Competence Center will be invited. to participate in the study. In order to document the improvement in patient care, morbidity and mortality through the implementation of the PNDS Still, deceased patients may be included in the cohort. The objective is to recruit a minimum of 200 adult patients and 300 pediatric patients so that the study has sufficient statistical power. The stratification of patients is made into 4 subgroups according to the form of the pathology: * Pediatric (juvenile arthritis systemic idiopathic) * Adult monocyclic (approximately 30% of cases) * Adult intermittent or polycyclic (30%) * Adult persistent or chronic (40%)

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged over 16 (age\> 16) meeting the diagnostic criteria of Yamaguchi or Fautrel criteria (appendix 5) * Aged 16 years or less (age ≤16 years) fulfilling the 2001 criteria for ILAR systemic form of juvenile idiopathic arthritis * Having signed a consent to participate in the cohort and in the collection of clinical and biological data; in accordance with the regulations, for patients who are minors or adults who are protected, the non-opposition of the legal representatives will be sought. * Affiliated to the "Régime National d'Assurance Maladie". Exclusion Criteria: * Other cause of relapsing infectious fever (such as tuberculosis, toxoplasmosis, deep abscesses, viroses, sepsis) or tumor (such as lymphomas) * Other defined inflammatory rheumatism such as rheumatoid arthritis, psoriatic arthritis, spondyloarthropathies. * Autoimmune inflammatory disease (systemic lupus erythematosus), granulomatosis (sarcoidosis, Blau syndrome), vasculitis (Behçet's disease, nodular arteritis), polymyositis and dermatomyositis. * Well-defined auto-inflammatory syndromes with unambiguous mutations, such as familial Mediterranean fever, cryopyrinopathies, TRAPS, mevalonate kinase deficiency. * Known macrophage activation syndromes of genetic origin. * Patients unable to understand the information leaflet and sign the informed consent form * Patients not affiliated to the "Régime National d'Assurance Maladie"

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Still disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adult-onset Still disease juvenile idiopathic arthritis Rare Diseases systemic-onset juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Still disease Still disease, juvenile onset Still's disease, adult-onset

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Major study launches to unravel mysteries of rare still disease in kids and adults

What the study statuses mean